Juvenal Tobin W 4

What Happened

• Juvenal W. Tobin, Chief Commercial Officer of Castle Biosciences (CSTL), sold 20,863 shares on March 12, 2026. The weighted-average sale price was $25.24, for total proceeds of approximately $526,582. The transaction was reported on a Form 4 filed March 16, 2026.
• This was a sale (liquidation) rather than a purchase; sales by insiders are commonly routine and may be pre-planned.

Key Details

• Transaction date: March 12, 2026. Filing date: March 16, 2026 (filed within the typical 2 business-day window).
• Price(s): Weighted-average $25.24; executed in multiple trades at prices ranging from $24.90 to $25.70 (footnote).
• Shares sold: 20,863; Total proceeds: ~$526,582.
• Post-transaction shares owned: Not provided in the excerpt you supplied.
• Notable footnotes: F1 — sale was made pursuant to a Rule 10b5-1 trading plan adopted Dec 10, 2025. F2 — multiple-trade execution and the filer will provide detailed trade-by-trade prices/quantities upon request.
• Transaction type: Reported as an open-market/private sale (code S).

Context

• A 10b5-1 plan usually means the sale was pre-scheduled and does not necessarily reflect the insider’s current view of the company; it’s commonly used for planned liquidity.
• For retail investors, single insider sales are informative but not definitive evidence of company prospects—look for patterns (multiple insiders or repeated large sales) and combine with company fundamentals and news.